Comparison of plasma eotaxin family level in aspirin-induced and aspirin-tolerant asthma patients

Chest

Volumn 128, Issue 5, 2005, Pages 3127-3132

  Min, Ji Won ^a   Jang, An Soo ^a   Park, Se Min ^a   Lee, Seung Ha ^a   Lee, June Hyuk ^a   Park, Sung Woo ^a   Park, Choon Sik ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Aspirin; Asthma; Eosinophils; Eotaxin

Indexed keywords

ACETYLSALICYLIC ACID; CHEMOKINE; CHEMOKINE RECEPTOR; EOTAXIN; EOTAXIN 2; EOTAXIN 3; INTERLEUKIN 5; LIGAND; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASPIRIN INDUCED ASTHMA; ASPIRIN TOLERANT ASTHMA; ASTHMA; CELL DIFFERENTIATION; CLINICAL ARTICLE; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; HIGH RISK PATIENT; HUMAN; INFLAMMATORY CELL; MALE; NOSE POLYP; PRIORITY JOURNAL; PROTEIN FAMILY; PROVOCATION TEST;

EID: 28144435717     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.5.3127     Document Type: Article

References (32)

1. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-921
2. Stevenson DD. Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 1984; 74:617-622
3. Szczeklik A, Virchow C, Schmitz-Schumann M. Pathophysiology, pharmacology of aspirin-induced asthma. In: Page CP, Barnes PJ, eds. Pharmacology of asthma: handbook of experimental pharmacology. Berlin, Germany: Springer-Verlag, 1991; 291-314
4. Nasser SM, Pfister R, Christie PE, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996; 153:90-96
5. Sampson AP, Cowburn AS, Sladek K, et al. Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int Arch Allergy Immunol 1997; 113:355-357
6. Daugherty BL, Siciliano SJ, DeMartino JA, et al. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996; 183:2349-2354
7. Yang M, Hogan SP, Mahalingam S, et al. Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13 production and airway eosinophilia and hyperreactivity. J Allergy Clin Immunol 2003; 112:935-943
8. Ponath PD, Qin S, Post TW, et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996; 183:2437-2448
9. Park SW, Kim DJ, Chang HS, et al. Association of interleukin-5 and eotaxin with acute exacerbation of asthma. Int Arch Allergy Immunol 2003; 31:283-290
10. Jose PJ, Griffiths-Johnson DA, Collins PD, et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med 1994; 179:881-887
11. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996; 2:449-456
12. Garcia-Zepeda EA, Rothenberg ME, Weremowicz S, et al. Genomic organization, complete sequence, and chromosomal location of the gene for human eotaxin (SCYA11), an eosinophil-specific CC chemokine. Genomics 1997; 41:471-476
13. Nomiyama H, Osborne LR, Imai T, et al. Assignment of the human CC chemokine MPIF-2/eotaxin-2 (SCYA24) to chromosome 7q11.23. Genomics 1998; 49:339-340
14. Guo RF, Ward PA, Hu SM, et al. Molecular cloning and characterization of a novel human CC chemokine, SCYA26. Genomics 1999; 58:313-317
15. White JR, Imburgia C, Dul E, et al. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J Leukoc Biol 1997; 62:667-675
16. Patel VP, Kreider BL, Li Y, et al. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med 1997; 185:1163-1172
17. Ponath PD, Qin S, Ringler DJ, et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996; 97:604-612
18. National Institutes of Health. Global strategy for asthma management and prevention: NHLBI/WHO workshop report; National Heart, Lung, and Blood Institute. Bethesda, MD: National Institutes of Health; Publication No. 2002-3659
19. American Thoracic Society. Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1989; 136:225-244
20. Chai H, Farr RS, Froehlich LA, et al. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol 1975; 56:323-327
21. Park CS, Kim YY, Kang SY. Collection between RAST and skin test for inhalant offending allergens. J Kor Soc Allergol 1984; 3:1-9
22. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Middleton E Jr, Reed CE, Ellis EF, et al. Allergy: principles and practice. 4th ed. St. Louis, MO: CV Mosby, 1993; 1751
23. Kitaura M, Nakajima T, Imai T, et al. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem 1996; 271:7725-7730
24. Forssmann U, Uguccioni M, Loetscher P, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997; 185:2171-2176
25. Ying S, Robinson DS, Meng Q, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma: association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997; 27:3507-3516
26. Lamkhioued B, Renzi PM, Abi-Younes S, et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol, 1997; 159:4593-4601
27. Nakamura H, Weiss ST, Israel E, et al. Eotaxin and impaired lung function in asthma. Am J Respir Crit Care Med 1999; 160:1952-1956
28. Taha RA, Laberge S, Hamid Q, et al. Increased expression of the chemoattractant cytokines eotaxin, monocyte chemotactic protein-4, and interleukin-16 in induced sputum in asthmatic patients. Chest 2001; 120:595-601
29. Brown JR, Kleimberg J, Marini M, et al. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. Clin Exp Immunol 1998; 114:137-146
30. Berkman N, Ohnona S, Chung FK, et al. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol 2001; 24:682-687
31. Lilly CM, Woodruff PG, Camargo CA Jr, et al. Elevated plasma eotaxin levels in patients with acute asthma. J Allergy Clin Immunol 1999; 104:786-790
32. Pods R, Ross D, van Hulst S, et al. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy 2003; 58:1165-1170